Skip to content
Administration & Dosing

Pulsatile dosing

A dosing strategy that mimics the body’s natural pulsatile hormone release patterns. Used with growth hormone secretagogues to prevent receptor desensitization and maintain physiological GH release.

Frequently Asked Questions

What is Pulsatile dosing?
A dosing strategy that mimics the body’s natural pulsatile hormone release patterns. Used with growth hormone secretagogues to prevent receptor desensitization and maintain physiological GH release.
Why is Pulsatile dosing important in peptide research?
Understanding pulsatile dosing is essential for safe and effective peptide use. Proper administration technique directly impacts peptide bioavailability, therapeutic outcomes, and minimizes the risk of adverse effects or contamination.

Related Terms

Desensitization

A rapid decrease in receptor responsiveness to a peptide agonist despite continued exposure. Distinct from downregulation — desensitization involves receptor modification rather than reduced receptor numbers.

Cycling

The practice of using a peptide for a set period (on-cycle) followed by a break (off-cycle) to maintain receptor sensitivity, reduce side effects, and prevent tolerance. Typical cycles range from 4–12 weeks on, 2–4 weeks off.

Growth hormone secretagogue

A compound that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor or GHRH receptor. Includes peptides (ipamorelin, GHRP-2, GHRP-6) and the oral compound MK-677.

Related Peptide Profiles

CJC-1295

A synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile GH secretion. Available with or without DAC (Drug Affinity Complex).

Ipamorelin

A selective growth hormone secretagogue that stimulates GH release through the ghrelin receptor with minimal effect on cortisol or prolactin.

← Back to full glossary